Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
Temesgen Z. et al, (2022), The lancet respiratory medicine, 10, 237 - 246
S49 C-reactive protein as a biomarker for improved efficacy of lenzilumab in Covid-19 patients: results from the LIVE-AIR trial
Temesgen Z. et al, (2021), Developing treatments for covid-19
C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL
TEMESGEN Z. et al, (2021), Chest, 160, A2522 - A2524
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia
Temesgen Z. et al, (2020), Mayo clinic proceedings, 95, 2382 - 2394
An effective mouse model for adoptive cancer immunotherapy targeting neoantigens
Hanada K-I. et al, (2019), Jci insight, 4